blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2763701

EP2763701 - MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  25.10.2019
Database last updated on 23.04.2024
FormerThe patent has been granted
Status updated on  16.11.2018
FormerGrant of patent is intended
Status updated on  26.06.2018
FormerExamination is in progress
Status updated on  19.05.2017
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
ModernaTX, Inc.
200 Technology Square
Cambridge, MA 02139 / US
[2019/40]
Former [2018/51]For all designated states
Moderna Therapeutics, Inc.
320 Bent Street
Cambridge, Massachusetts 02141 / US
Former [2015/26]For all designated states
Moderna Therapeutics, Inc.
320 Bent Street
Cambridge, Massachusetts 02141 / US
Former [2014/33]For all designated states
Moderna Therapeutics, Inc.
200 Technology Square
Cambridge, MA 02139 / US
Inventor(s)01 / DE FOUGEROLLES, Antonin
66 Summit Avenue
Brookline, MA 02446 / US
02 / ROY, Atanu
115 Hill Street, nr. 9
Stoneham, MA 02180 / US
03 / SCHRUM, Jason P.
20 Watertown St.
Unit 129
Watertown MA 02472-2580 / US
04 / SIDDIQI, Suhaib
37 University Avenue
Burlington, MA 01803 / US
05 / HATALA, Paul
26 Monument Street, nr. 1
Charlestown, MA 02124 / US
06 / BANCEL, Stephane
c/o Moderna Therapeutics, Inc.
320 Bent Street
Cambridge, MA 02141 / US
 [2015/48]
Former [2015/34]01 / DE FOUGEROLLES, Antonin
66 Summit Avenue
Brookline, MA 02446 / US
02 / ROY, Atanu
115 Hill Street, nr. 9
Stoneham, MA 02180 / US
03 / SCHRUM, Jason P.
20 Watertown St.
Unit 129
Watertown MA 02472-2580 / US
04 / SIDDIQI, Suhaib
37 University Avenue
Burlington, MA 01803 / US
05 / HATALA, Paul
26 Monument Street, nr. 1
Charlestown, MA 02124 / US
06 / BANCEL, Stephane
320 Bent Street
Cambridge, MA 02141 / US
Former [2014/33]01 / DE FOUGEROLLES, Antonin
66 Summit Avenue
Brookline, MA 02446 / US
02 / ROY, Atanu
115 Hill Street, nr. 9
Stoneham, MA 02180 / US
03 / SCHRUM, Jason P.
20 Watertown St.
Unit 129
Watertown MA 02472-2580 / US
04 / SIDDIQI, Suhaib
37 University Avenue
Burlington, MA 01803 / US
05 / HATALA, Paul
26 Monument Street, nr. 1
Charlestown, MA 02124 / US
06 / BANCEL, Stephane
200 Technology Square
Boston, MA 02139 / US
Representative(s)Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
[2018/51]
Former [2014/33]Vossius & Partner
Siebertstrasse 4
81675 München / DE
Application number, filing date12838676.003.10.2012
[2018/51]
WO2012US58519
Priority number, dateUS201161542533P03.10.2011         Original published format: US 201161542533 P
[2014/33]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013052523
Date:11.04.2013
Language:EN
[2013/15]
Type: A1 Application with search report 
No.:EP2763701
Date:13.08.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 11.04.2013 takes the place of the publication of the European patent application.
[2014/33]
Type: B1 Patent specification 
No.:EP2763701
Date:19.12.2018
Language:EN
[2018/51]
Search report(s)International search report - published on:US11.04.2013
(Supplementary) European search report - dispatched on:EP13.11.2015
ClassificationIPC:A61K48/00, C07H21/02, C07H21/04
[2014/33]
CPC:
A61K48/0066 (EP,IL,KR,RU,US); C07K14/535 (IL,KR,US); A61K38/193 (EP,IL,US);
A61K48/0033 (KR); A61K48/0075 (KR); A61K9/0019 (KR);
A61K9/0021 (KR); A61K9/5123 (KR); A61P37/04 (EP);
A61P43/00 (EP); C07H21/02 (EP,IL,RU,US); C12N15/11 (IL,RU,US);
C12N15/67 (EP,IL,RU,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/33]
Extension statesBA02.05.2014
ME02.05.2014
TitleGerman:MODIFIZIERTE NUKLEOSIDE, NUKLEOTIDE UND NUKLEINSÄUREN UND VERWENDUNGEN DAVON[2014/33]
English:MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF[2014/33]
French:NUCLÉOSIDES, NUCLÉOTIDES ET ACIDES NUCLÉIQUES MODIFIÉS, ET LEURS UTILISATIONS[2014/33]
Entry into regional phase02.05.2014National basic fee paid 
02.05.2014Search fee paid 
02.05.2014Designation fee(s) paid 
02.05.2014Examination fee paid 
Examination procedure02.05.2014Examination requested  [2014/33]
13.06.2016Amendment by applicant (claims and/or description)
18.05.2017Despatch of a communication from the examining division (Time limit: M06)
24.11.2017Reply to a communication from the examining division
27.03.2018Despatch of a communication from the examining division (Time limit: M04)
24.05.2018Reply to a communication from the examining division
27.06.2018Communication of intention to grant the patent
06.11.2018Fee for grant paid
06.11.2018Fee for publishing/printing paid
06.11.2018Receipt of the translation of the claim(s)
Divisional application(s)EP18213451.0  / EP3492109
EP19216461.4  / EP3682905
EP21210754.4  / EP4015005
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  18.05.2017
Opposition(s)20.09.2019No opposition filed within time limit [2019/48]
Fees paidRenewal fee
27.10.2014Renewal fee patent year 03
27.10.2015Renewal fee patent year 04
27.10.2016Renewal fee patent year 05
27.10.2017Renewal fee patent year 06
29.10.2018Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU03.10.2012
AL19.12.2018
AT19.12.2018
CY19.12.2018
CZ19.12.2018
DK19.12.2018
EE19.12.2018
ES19.12.2018
FI19.12.2018
HR19.12.2018
IT19.12.2018
LT19.12.2018
LV19.12.2018
MC19.12.2018
MK19.12.2018
MT19.12.2018
NL19.12.2018
PL19.12.2018
RO19.12.2018
RS19.12.2018
SE19.12.2018
SI19.12.2018
SK19.12.2018
SM19.12.2018
TR19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
IS19.04.2019
PT19.04.2019
[2022/31]
Former [2021/34]HU03.10.2012
AL19.12.2018
AT19.12.2018
CY19.12.2018
CZ19.12.2018
DK19.12.2018
EE19.12.2018
ES19.12.2018
FI19.12.2018
HR19.12.2018
IT19.12.2018
LT19.12.2018
LV19.12.2018
MC19.12.2018
MT19.12.2018
NL19.12.2018
PL19.12.2018
RO19.12.2018
RS19.12.2018
SE19.12.2018
SI19.12.2018
SK19.12.2018
SM19.12.2018
TR19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
IS19.04.2019
PT19.04.2019
Former [2021/32]HU03.10.2012
AL19.12.2018
AT19.12.2018
CY19.12.2018
CZ19.12.2018
DK19.12.2018
EE19.12.2018
ES19.12.2018
FI19.12.2018
HR19.12.2018
IT19.12.2018
LT19.12.2018
LV19.12.2018
MC19.12.2018
NL19.12.2018
PL19.12.2018
RO19.12.2018
RS19.12.2018
SE19.12.2018
SI19.12.2018
SK19.12.2018
SM19.12.2018
TR19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
IS19.04.2019
PT19.04.2019
Former [2021/26]AL19.12.2018
AT19.12.2018
CY19.12.2018
CZ19.12.2018
DK19.12.2018
EE19.12.2018
ES19.12.2018
FI19.12.2018
HR19.12.2018
IT19.12.2018
LT19.12.2018
LV19.12.2018
MC19.12.2018
NL19.12.2018
PL19.12.2018
RO19.12.2018
RS19.12.2018
SE19.12.2018
SI19.12.2018
SK19.12.2018
SM19.12.2018
TR19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
IS19.04.2019
PT19.04.2019
Former [2020/29]AL19.12.2018
AT19.12.2018
CZ19.12.2018
DK19.12.2018
EE19.12.2018
ES19.12.2018
FI19.12.2018
HR19.12.2018
IT19.12.2018
LT19.12.2018
LV19.12.2018
MC19.12.2018
NL19.12.2018
PL19.12.2018
RO19.12.2018
RS19.12.2018
SE19.12.2018
SI19.12.2018
SK19.12.2018
SM19.12.2018
TR19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
IS19.04.2019
PT19.04.2019
Former [2020/17]AL19.12.2018
AT19.12.2018
CZ19.12.2018
DK19.12.2018
EE19.12.2018
ES19.12.2018
FI19.12.2018
HR19.12.2018
IT19.12.2018
LT19.12.2018
LV19.12.2018
NL19.12.2018
PL19.12.2018
RO19.12.2018
RS19.12.2018
SE19.12.2018
SI19.12.2018
SK19.12.2018
SM19.12.2018
TR19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
IS19.04.2019
PT19.04.2019
Former [2020/13]AL19.12.2018
AT19.12.2018
CZ19.12.2018
DK19.12.2018
EE19.12.2018
ES19.12.2018
FI19.12.2018
HR19.12.2018
IT19.12.2018
LT19.12.2018
LV19.12.2018
NL19.12.2018
PL19.12.2018
RO19.12.2018
RS19.12.2018
SE19.12.2018
SI19.12.2018
SK19.12.2018
SM19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
IS19.04.2019
PT19.04.2019
Former [2019/48]AL19.12.2018
AT19.12.2018
CZ19.12.2018
DK19.12.2018
EE19.12.2018
ES19.12.2018
FI19.12.2018
HR19.12.2018
IT19.12.2018
LT19.12.2018
LV19.12.2018
NL19.12.2018
PL19.12.2018
RO19.12.2018
RS19.12.2018
SE19.12.2018
SK19.12.2018
SM19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
IS19.04.2019
PT19.04.2019
Former [2019/46]AL19.12.2018
AT19.12.2018
CZ19.12.2018
EE19.12.2018
ES19.12.2018
FI19.12.2018
HR19.12.2018
IT19.12.2018
LT19.12.2018
LV19.12.2018
NL19.12.2018
PL19.12.2018
RO19.12.2018
RS19.12.2018
SE19.12.2018
SK19.12.2018
SM19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
IS19.04.2019
PT19.04.2019
Former [2019/39]AL19.12.2018
CZ19.12.2018
EE19.12.2018
ES19.12.2018
FI19.12.2018
HR19.12.2018
IT19.12.2018
LT19.12.2018
LV19.12.2018
NL19.12.2018
PL19.12.2018
RO19.12.2018
RS19.12.2018
SE19.12.2018
SK19.12.2018
SM19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
IS19.04.2019
PT19.04.2019
Former [2019/37]AL19.12.2018
CZ19.12.2018
EE19.12.2018
ES19.12.2018
FI19.12.2018
HR19.12.2018
IT19.12.2018
LT19.12.2018
LV19.12.2018
NL19.12.2018
PL19.12.2018
RO19.12.2018
RS19.12.2018
SE19.12.2018
SM19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
PT19.04.2019
Former [2019/35]AL19.12.2018
CZ19.12.2018
ES19.12.2018
FI19.12.2018
HR19.12.2018
IT19.12.2018
LT19.12.2018
LV19.12.2018
NL19.12.2018
PL19.12.2018
RS19.12.2018
SE19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
PT19.04.2019
Former [2019/34]AL19.12.2018
FI19.12.2018
HR19.12.2018
IT19.12.2018
LT19.12.2018
LV19.12.2018
NL19.12.2018
RS19.12.2018
SE19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
PT19.04.2019
Former [2019/33]AL19.12.2018
FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
NL19.12.2018
RS19.12.2018
SE19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
PT19.04.2019
Former [2019/30]AL19.12.2018
FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
NL19.12.2018
RS19.12.2018
SE19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
Former [2019/26]AL19.12.2018
FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
RS19.12.2018
SE19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
Former [2019/25]FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
RS19.12.2018
SE19.12.2018
BG19.03.2019
NO19.03.2019
GR20.03.2019
Former [2019/23]FI19.12.2018
HR19.12.2018
LT19.12.2018
LV19.12.2018
BG19.03.2019
NO19.03.2019
Former [2019/22]FI19.12.2018
LT19.12.2018
BG19.03.2019
NO19.03.2019
Former [2019/21]FI19.12.2018
LT19.12.2018
NO19.03.2019
Former [2019/20]LT19.12.2018
NO19.03.2019
Documents cited:Search[A]WO2011012316  (UNIV MUENCHEN L MAXIMILIANS [DE], et al) [A] 1-10 * page 12 *;
 [A]  - KARIKÓ KATALIN ET AL, "Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, vol. 16, no. 11, doi:10.1038/MT.2008.200, ISSN 1525-0024, (20081101), pages 1833 - 1840, (20080916), XP002598556 [A] 1-10 * abstract *

DOI:   http://dx.doi.org/10.1038/mt.2008.200
 [A]  - LUIGI WARREN ET AL, "Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA", CELL STEM CELL, CELL PRESS, UNITED STATES, vol. 7, no. 5, doi:10.1016/J.STEM.2010.08.012, ISSN 1875-9777, (20101105), pages 618 - 630, URL: http://www.sciencedirect.com/science/article/pii/S1934590910004340, XP002693059 [A] 1-10 * abstract *

DOI:   http://dx.doi.org/10.1016/J.STEM.2010.08.012
International search[A]US2010047261  (HOERR INGMAR [DE], et al);
 [X]US2011143397  (KARIKO KATALIN [US], et al);
 [T]US2012251618  (SCHRUM JASON P [US], et al)
by applicantUS4270537
 US4596556
 US4790824
 US4886499
 US4940460
 US4941880
 US5015235
 US5064413
 US5141496
 US5190521
 US5208020
 US5312335
 US5328483
 US5334144
 US5339163
 US5383851
 US5417662
 US5466220
 US5475092
 US5480381
 US5503627
 US5520639
 US5527288
 US5569189
 US5585499
 US5599302
 WO9713537
 US5649912
 WO9737705
 US5704911
 US5846545
 US5893397
 WO9934850
 US5993412
 US2011143397
 US2011177495
    - KARIKO et al., Mol Ther., (20080000), vol. 16, no. 11, pages 1833 - 1840
    - ALBRECHT, Immunotherapy, (20100000), vol. 2, no. 6, pages 795 - 8
    - CARON et al., Mol Ther., (20010000), vol. 3, no. 3, pages 310 - 8
    - EL-ANDALOUSSI et al., Curr Pharm Des., (20050000), vol. 11, no. 28, pages 3597 - 611
    - DESHAYES et al., Cell Mol Life Sci., (20050000), vol. 62, no. 16, pages 1839 - 49
    - CARILLO et al., SIAM J. Applied Math., (19880000), vol. 48, page 1073
    - MUSUNURU K et al., "From noncoding variant to phenotype via SORTI at the lp 13 cholesterol locus", Nature, (20100000), vol. 466, pages 714 - 721
    - MEYERS; MILLER, CABIOS, (19890000), vol. 4, pages 11 - 17
    - ESVELT et al., Nature, (20110000), vol. 472, no. 7344, pages 499 - 503
    - CHELLISERRYKATTIL; ELLINGTON, Nature Biotechnology, (20040000), vol. 22, no. 9, pages 1155 - 1160
    - PADILLA; SOUSA, Nucleic Acids Research, (20020000), vol. 30, no. 24, page e128
    - ROBBINS et al., Oligonucleotides, (20090000), vol. 19, pages 89 - 102
    - KARIKO et al., Immunity, (20050000), vol. 23, pages 165 - 175
    - WARREN et al., Cell Stem Cell, (20100000), vol. 7, pages 618 - 630
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.